Abstract
Due to the fact that the percentage of aged subjects in the populations of industrialized countries is dramatically increasing, the scientific community has been obligated to focus their attention on age related disease states and peculiar consequences of aging such as, frailty. Frailty is defined as a syndrome of decreased reserve and resistance to stressors and is clinically expressed as muscle weakness, poor exercise tolerance, factors related to body composition, sarcopenia, and lower extremity mobility. Some biochemical markers of frailty in older persons, including pro-inflammatory markers, hormones and free radicals have been suggested. However, there is growing evidence that a rise in insulin resistance [IR] occurs as individuals age and IR is not only considered a simple metabolic finding, but has been identified as a major risk factor for many age-related diseases due to altered lipid metabolism, increased inflammatory state, impaired endothelial functioning, pro-thrombotic status and atherosclerosis. Considering that IR is related to many of the clinical features of frailty such as, skeletal muscle weakness, lower extremity mobility disability, cognitive decline and body composition changes, we will analyze the relationships among IR and such individual components while highlighting potential pathophysiologic mechanisms of IR on the activation of the downward spiral of the frailty syndrome in older persons. In particular, we will address the issue that IR may also be considered a pivotal biological component of some clinical aspects of the frailty syndrome in aging individuals.
Keywords: Insulin resistance, frailty syndrome, aging
Current Pharmaceutical Design
Title: Is There A Relationship Between Insulin Resistance and Frailty Syndrome?
Volume: 14 Issue: 4
Author(s): Giuseppe Paolisso and Angela Marie Abbatecola
Affiliation:
Keywords: Insulin resistance, frailty syndrome, aging
Abstract: Due to the fact that the percentage of aged subjects in the populations of industrialized countries is dramatically increasing, the scientific community has been obligated to focus their attention on age related disease states and peculiar consequences of aging such as, frailty. Frailty is defined as a syndrome of decreased reserve and resistance to stressors and is clinically expressed as muscle weakness, poor exercise tolerance, factors related to body composition, sarcopenia, and lower extremity mobility. Some biochemical markers of frailty in older persons, including pro-inflammatory markers, hormones and free radicals have been suggested. However, there is growing evidence that a rise in insulin resistance [IR] occurs as individuals age and IR is not only considered a simple metabolic finding, but has been identified as a major risk factor for many age-related diseases due to altered lipid metabolism, increased inflammatory state, impaired endothelial functioning, pro-thrombotic status and atherosclerosis. Considering that IR is related to many of the clinical features of frailty such as, skeletal muscle weakness, lower extremity mobility disability, cognitive decline and body composition changes, we will analyze the relationships among IR and such individual components while highlighting potential pathophysiologic mechanisms of IR on the activation of the downward spiral of the frailty syndrome in older persons. In particular, we will address the issue that IR may also be considered a pivotal biological component of some clinical aspects of the frailty syndrome in aging individuals.
Export Options
About this article
Cite this article as:
Paolisso Giuseppe and Abbatecola Marie Angela, Is There A Relationship Between Insulin Resistance and Frailty Syndrome?, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497750
DOI https://dx.doi.org/10.2174/138161208783497750 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of <i>p</i>-Hydroxybenzaldehyde, Vanillin, and Syringaldehyde on
Protein Tyrosine Phosphatase 1B Activity
Current Enzyme Inhibition Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Indazole Derivatives Effective against Gastrointestinal Diseases
Current Topics in Medicinal Chemistry Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Serum Zinc and β D Glucuronidase Enzyme Level in Type 2 Diabetes Mellitus with Periodontitis
Current Diabetes Reviews By Passing Microbial Resistance: Xylitol Controls Microorganisms Growth by Means of Its Anti-Adherence Property
Current Pharmaceutical Biotechnology CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Current Medicinal Chemistry Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Elucidation of Cellular Metabolism Via Metabolomics and Stable-Isotope Assisted Metabolomics
Current Pharmaceutical Biotechnology Proteinase Inhibitors: A Promising Drug Class for Treating Leishmaniasis
Current Drug Targets Antioxidant Therapy Alters Brain MAPK-JNK and BDNF Signaling Path-ways in Experimental Diabetes Mellitu s
Current Neurovascular Research Hyperglycemia and Perioperative Glucose Management
Current Pharmaceutical Design Dendritic Cell-Based Immunotherapy in Thyroid Malignancies
Current Drug Targets - Immune, Endocrine & Metabolic Disorders New Frontiers in Alcoholism and Addiction Treatment
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits
Current Pharmaceutical Biotechnology Cellular Senescence and ApoE4: Their Repercussions in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives
Current Medicinal Chemistry Drugs and Aggression
Recent Patents on CNS Drug Discovery (Discontinued)